Abstract Background Circulating tumor DNA (ctDNA) assays can transform patient management by enabling molecular residual disease (MRD) detection, prognosis prediction, and treatment monitoring. Here, we report clinical performance of Signatera Genome, a whole-genome sequencing (WGS)-based ctDNA assay, in a diverse pan-...
Mridula A. George, Gary S. Schwartz, W. McHayleh et al.· The Oncologist· 0 citations
Response assessment of primary kidney tumors in the consolidation cytoreductive and neoadjuvant settings offers a unique opportunity to inform postoperative adaptive treatment strategies. Yet, systematic analyses of nephrectomy specimens post immune checkpoint inhibition (ICI) therapies are lacking. We retrospectively...
P. Kapur, A. Christie, V. Jarmale et al.· Modern Pathology· 0 citations
ML models using preoperative variables achieved moderate discrimination for predicting adverse pathological features in UTUC and external validation and prospective assessment of clinical utility are necessary before informing preoperative patient selection.
Philipp Korn, Maximilian Pallauf, S. Lokeshwar et al.· Urologic oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.